Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Holding APLS?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.37Last Year’s EPS
-$0.73Same Quarter Last Year
Moderate Buy
Based on 19 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2024
|% Change Since: 16.28%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong demand growth for SYFOVRE and promising Phase III results for Empaveli, indicating potential for significant market impact. However, these positives were offset by revenue decline for SYFOVRE due to gross to net adjustments, slowed market growth, and challenges in Europe. Overall, the company remains optimistic about long-term prospects and profitability but faces immediate hurdles.Company Guidance
During the third quarter of 2024, Apellis Pharmaceuticals reported significant milestones and provided forward-looking guidance, emphasizing their strategic focus on SYFOVRE and Empaveli. SYFOVRE's commercial vial demand grew by 7% quarter-over-quarter, with 84,500 vials shipped, maintaining a market leadership with a 65% market share. However, SYFOVRE's net product revenue of $152 million reflected a 1.7% decline from the previous quarter, attributed to increases in gross-to-net adjustments, which resulted from strategic contracting decisions and rebates that took effect. Despite these challenges, the company remains optimistic, projecting low single-digit percentage vial growth and modest net revenue growth for the fourth quarter of 2024. For Empaveli, U.S. product revenue in PNH was $24.6 million, a 3% increase from the same period last year, supported by a 97% compliance rate. Apellis plans to file their supplemental NDA for Empaveli in early 2025, with anticipation of capturing a significant market share in C3G and IC-MPGN, highlighting the potential of their C3-targeted therapies across multiple therapeutic areas. The company's financial strategy underscores a strong cash position of $397 million and a path to positive cash flow, with expectations of gross-to-net percentages stabilizing in the low to mid-20% range through 2025.Strong Growth in SYFOVRE Demand
Commercial vial demand for SYFOVRE grew by 7% quarter-over-quarter, maintaining market leadership with 84,500 commercial vials shipped.
Positive Phase III VALIANT Results
Presented groundbreaking Phase III VALIANT results with Empaveli for C3G and IC-MPGN, showing significant efficacy and potential to redefine treatment paradigms.
Empaveli Revenue and Compliance
Empaveli generated $24.6 million in U.S. product revenue for PNH, with a 97% compliance rate.
Regulatory Advancements
Received FDA feedback that allows filing a supplemental NDA with 6-month data for C3G and IC-MPGN, without needing full 52-week data.
Real-World Data Reinforcement
Real-world data reaffirm SYFOVRE's efficacy, with anticipated third-party publications supporting treatment benefits.
---
APLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
APLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $28.56 | $28.08 | -1.68% |
| Aug 01, 2024 | $39.60 | $36.00 | -9.09% |
| May 07, 2024 | $48.81 | $43.90 | -10.06% |
| Feb 27, 2024 | $71.73 | $69.35 | -3.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Apellis Pharmaceuticals Inc (APLS) report earnings?
Apellis Pharmaceuticals Inc (APLS) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Apellis Pharmaceuticals Inc (APLS) earnings time?
Apellis Pharmaceuticals Inc (APLS) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is APLS EPS forecast?
APLS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.37.
---